Can the THC concentration predict the number of patients with cannabis‐related diagnoses?
Drug and Alcohol Review · 2024
DOI: 10.1111/dar.13923 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug and Alcohol Review, 2024. Verfasst von Jakob Manthey und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Interdisciplinary Addiction Research, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Ger…. Hauptthemen laut MEDLINE: Dronabinol, Marijuana Abuse. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Central Institute of Statutory Health Insurance Physicians.
Abstract (Originalsprache)
Introduction
The use of high‐potency cannabis products is associated with an increased risk of mental disorders. This study investigates whether the rising THC concentration in Germany is associated with an increase in cannabis‐related diagnoses.
Methods
The number of insured persons with at least one cannabis‐related ICD‐10 F12 diagnosis (e.g., harmful use, dependence) in outpatient care was provided by statutory health insurance funds between 2009 and 2021. The dependent variable is the ratio of (a) the number of insured persons with at least one F12 diagnosis to (b) all insured persons who have used cannabis in the last year. Information on THC concentration in cannabis flower was provided by law enforcement agencies. Using generalised mixed linear models, the dependent variable was predicted by the median THC concentration in cannabis flower.
Results
The regression results show that an increase in THC concentration by one percentage point is significantly associated with an increase in the proportion of diagnoses (women: +0.17; men: +0.42). THC concentration positively predicted the proportion of diagnoses in all 16 federal states for men and in 15 federal states for women. Discussion and Conclusions Compared to low‐potency products, using high‐potency products may pose additional health risks, which may be particularly pronounced in men. Acknowledging the limitations of the ecological study design and uncertainties inherent to the analysed data, further investigations on the sex‐specific impact of THC exposure are required. Limiting the THC concentration in cannabis products and closely monitoring THC consumption in the population appears necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre of Interdisciplinary Addiction Research, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Psychiatry, Medical Faculty, University of Leipzig, Leipzig, Germany.
- Zentralinstitut für die kassenärztliche Versorgung, Berlin, Germany.
- IFT Institut für Therapieforschung, Mental Health and Addiction Research, Munich, Germany.
- Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich Marchioninistrasse 17, Munich, Germany.
ORCID-Profile: Jakob Manthey, Moritz Rosenkranz, Larissa Schwarzkopf
Förderung
- Central Institute of Statutory Health Insurance Physicians
Zitieren
APA
Manthey, J., Rosenkranz, M., Jonas, B., & Schwarzkopf, L. (2024). Can the THC concentration predict the number of patients with cannabis‐related diagnoses?. Drug and Alcohol Review. https://doi.org/10.1111/dar.13923
Vancouver
Manthey J, Rosenkranz M, Jonas B, Schwarzkopf L. Can the THC concentration predict the number of patients with cannabis‐related diagnoses?. Drug and Alcohol Review. 2024. doi:10.1111/dar.13923
BibTeX
@article{Manthey2024,
author = {Manthey, Jakob and Rosenkranz, Moritz and Jonas, Benjamin and Schwarzkopf, Larissa},
title = {Can the THC concentration predict the number of patients with cannabis‐related diagnoses?},
journal = {Drug and Alcohol Review},
year = {2024},
doi = {10.1111/dar.13923}
}
EUVIMED